The involvement of PP2A in the regulation of apoptotic and proliferative signaling pathways in DIPG tumor samples suggests that PP2A targeting should be explored further as a primary and adjunctive therapeutic agent for DIPG. This evidence concerns the gene PTPA and neoplasm.